Emergent eyes BRIC markets for its anthrax vaccine
This article was originally published in Scrip
Executive Summary
Emergent BioSolutions, a US biopharmaceutical company, hopes to introduce its anthrax vaccine and another vaccine under development for tuberculosis in certain countries in the "BRIC" grouping – Brazil, Russia, India and China - as it looks beyond its home market for growth opportunities.